BioValley Basel Association
Elisabethenstr. 15
4051 Basel, Switzerland
Agenda
Welcome at EY Basel by Biotech Lead Switzerland and Managing Partner Basel Office
Gabriela Güntherodt
Introduction by BioValley Basel/BioBAC Subchapter
Thomas Möller, Anne Grahl, Ariane Hegel Reynolds, Hansres Engel
Startups pitching - (pre)seed stage (12 min + 8 min Q&A)
GlioCART GmbH – Dieter Willmann (CEO) & Patrice Zeis (COO) – 11.2025 in Basel/ Allschwil
GlioCART is a University of Basel spin-off developing a first-in-class, dual-action CAR-T cell therapy for glioblastoma, designed to combine targeted tumor killing with local immune microenvironment reprogramming.
Sefit Health AG – Elena Börlin (CEO) & Eric Leung (COO) – 08.2024 in Basel/Reinach
Swiss medtech startup offering configurable digital exposure therapy and training in situations of sensory overload for neurodiverse patients such as autism or ADHD through a blended-therapy approach. The VR based software product is planned to be clinically validated.
Myria Biosciences AG – Steven Schmitt (CEO) & Irene Wüthrich (COO) – 01.2022 in Basel/Zurich
Thousands of novel molecules per week, at 1% of the cost — designed by AI, built by biology — setting a new standard in drug discovery of peptides.